| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 initiation example | Phase 3 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 3 initiation example | Phase 3 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 3 initiation example | Phase 3 | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
MBX Biosciences, Inc.$61.05
-5.13 (-7.81%)
C 48Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.52 B
EPS
-2.21
P/E Ratio
-
Value Trade
13.99 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
18.47 M
Operating CF
-20.21 M
Total Assets
452.70 M
Total Liabilities
14.95 M
Equity
437.76 M
D/E Ratio
12,345
-8.66 %
Week
-4.9 %
1 Month
-14.52 %
3 Month
18.71 %
6 Month
38.48 %
5 Year
38.48 %
All Time
Cash Data
Cash Position
439.98 M
Monthly Burn
6.74 M
Runway
63.4 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
851.96 K
52 Week Range
9.43 - 45.85
% held by Insiders
38.15 %
% held by Institutions
84.87 %
Enterprise Value
1.08 B
Total Shares
47.58 M
Short %
19.4 %
Float Shares
28.64 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MBX Biosciences, Inc.
114Total events
2Upcoming
18Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 2
Event history 112
Q3 2026
◆Trial InitiationcanvuparatideTrial
Initiation of Phase 3 confirmatory trial for canvuparatide in hypoparathyroidism
chronic hypoparathyroidismsource ↗
Q3 2026
◆First Patient DosedcanvuparatideTrial
First patient enrollment expected in Phase 3 trial of canvuparatide
chronic hypoparathyroidismsource ↗
Q3 2026
●Development Candidate NominationPreclinical
GLP-1/GIP/GCG receptor prodrug candidate nomination expected
obesitysource ↗
Q3 2026
◆Development Candidate NominationPreclinical
Nomination of GLP-1/GIP/GCGR triple agonist prodrug candidate for obesity
obesitysource ↗
Q3 2026
◆Trial InitiationcanvuparatideTrial
Phase 3 trial initiation for once-weekly canvuparatide
hypoparathyroidismsource ↗
Q3 2026
◆Development Candidate NominationPreclinical
Nomination of GLP-1/GIP/GCGR triple-agonist prodrug candidate
obesitysource ↗
Jun 13, 2026
◆Oral PresentationcanvuparatidePresentation
Full results from 12-week Avail Phase 2 trial of once-weekly canvuparatide presented at ENDO 2026
chronic hypoparathyroidismsource ↗
Jun 12, 2026
◆Oral PresentationcanvuparatidePresentation
One-year open-label extension data from Phase 2 trial of once-weekly canvuparatide presented at 3rd Parathyroid Summit during ENDO 2026
chronic hypoparathyroidismsource ↗
Jun 12, 2026
◆R&D DaycanvuparatidePresentation
Virtual investor event to discuss canvuparatide presentations at ENDO 2026
chronic hypoparathyroidismsource ↗
Jun 12, 2026
▲Full ResultscanvuparatideClinical Data
Full results from 12-week Avail Phase 2 trial announced
chronic hypoparathyroidismsource ↗
Jun 3, 2026
Drug Pipeline Intelligence
C48
Pipeline Score $310M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 72%
Micro Cap (rank 256 of 911)
Percentile RankMBX Biosciences, Inc. carries a moderate pipeline score (48/100), with $774M risk-adjusted pipeline value, led by MBX 4291 in Obesity (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MBX 4291 Small molecule | Obesity | Phase 1 | NCT07142707 | 14% | $463M | RECRUITING | 124 | FAST | C (58) | Oct 30, 2026 | LOW_RISK | LOW Jun 9, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
canvuparatide | chronic hypoparathyroidism | Phase 2 | 2026-06-12 | 57% responder rate at one year; 63% of canvuparatide-treated patients achieved the primary composite endpoint at 12 weeks; 31% of placebo-treated patients achieved the primary composite endpoint at 12 weeks (p=0.042); 90% retention rate in the OLE study Read More | MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Read More | |
canvuparatide | chronic hypoparathyroidism | Phase 2 | 2026-06-12 | 57% responder rate at one year; 63% of canvuparatide-treated patients achieved the primary composite endpoint at 12 weeks; 31% of placebo-treated patients achieved the primary composite endpoint at 12 weeks (p=0.042); 90% retention rate in the OLE study Read More | MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Read More | |
canvuparatide | chronic hypoparathyroidism | Phase 2 | 2026-06-12 | 57% responder rate at one year; 63% of canvuparatide-treated patients achieved the primary composite endpoint at 12 weeks; 31% of placebo-treated patients achieved the primary composite endpoint at 12 weeks (p=0.042); 90% retention rate in the OLE study Read More | MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MBX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MBX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MBXMBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences announced positive one-year data for canvuparatide, a potential treatment for chronic hypoparathyroidism. The open-label extension study showed a 57% responder rate, consistent with previous Phase 2 results. Patients maintained normal serum calcium levels and experienced improved kidney function. The company plans to initiate a Phase 3 trial in Q3 2026.
Read more →MBXMBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
MBX Biosciences will host a virtual investor event on June 12, 2026, to discuss data on once-weekly canvuparatide. Presentations will include one-year open-label extension data and results from the 12-week Phase 2 trial at the ENDO 2026 conference. Notable experts will join the discussion, highlighting the company's advancements in peptide therapies.
Read more →MBXMBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
MBX Biosciences will present at the Jefferies 2026 Global Healthcare Conference in New York City. The presentation is scheduled for June 3, 2026, and will feature insights from CEO Kent Hawryluk and CMO Sam Azoulay. The company focuses on precision peptide therapies for endocrine and metabolic disorders and is advancing its pipeline, including candidates in various development phases.
Read more →MBXMBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences has provided an update on its obesity portfolio, highlighting preliminary Phase 1 data for MBX 4291, which shows a mean weight loss of 7% at 8 weeks. The drug was generally well tolerated, with minimal adverse events reported. The company is also advancing MBX 5765 as a new candidate and remains on track for further data releases in 2026.
Read more →MBX▲ +8.1%on this news· ran to +28% by day 1shared move
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
MBX Biosciences has appointed Mark R. Soued as Chief Commercial Officer, bringing over two decades of experience in commercial leadership within biopharmaceuticals. His expertise includes product launches and market access, which will support MBX's commercialization efforts. The company is advancing a pipeline of precision peptide therapies targeting endocrine and metabolic disorders.
Read more →MBX▲ +8.1%on this news· ran to +28% by day 1shared move
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-week
MBX Biosciences reported its first quarter 2026 financial results, highlighting advancements in its pipeline including the Phase 2 trial results of canvuparatide, which has been accepted for oral presentation at the ENDO 2026 annual meeting. The company is on track to initiate a Phase 3 trial of canvuparatide by Q3 2026 and plans to host an Obesity Day to present initial data from the Phase 1 trial of MBX 4291. With a significant cash reserve, MBX appears well positioned for future developments.
Read more →MBXMBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
MBX Biosciences will host an in-person and virtual Obesity Day on May 11, 2026, to discuss its expanding obesity portfolio. The event will feature experts Richard DiMarchi and Katherine H. Saunders, who will address treatment gaps in obesity. Management will present updates on their Precision Endocrine Peptide platform and ongoing product candidates.
Read more →MBX▼ -5.1%on this news
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MBX Biosciences has granted an equity inducement award to Karen Basbaum as she joins the company as Chief Business Officer. The award includes options for 130,000 shares at an exercise price of $32.29, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting top talent.
Read more →MBXMBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
MBX Biosciences reported its financial results for Q4 and full year 2025, highlighting significant progress in its clinical pipeline. The company is set to initiate a Phase 3 trial for canvuparatide in Q3 2026 after a successful FDA meeting. Additionally, MBX is advancing its obesity pipeline and has a strong cash position to support operations into 2029.
Read more →MBXMBX Biosciences Appoints Karen Basbaum as Chief Business Officer
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
Read more →MBX▼ -5.2%on this newsshared move
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences has successfully completed an End-of-Phase 2 meeting with the FDA regarding its Phase 3 trial for canvuparatide, a treatment for chronic hypoparathyroidism. The company plans to initiate the trial in Q3 2026, with a focus on patient-centric dosing. The treatment has also received orphan drug designation in Europe, further supporting its development.
Read more →MBX▼ -8.5%on this newsshared move
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism Following End-of-Phase 2 meeting, MBX remains on track to initiat
MBX Biosciences has successfully completed an End-of-Phase 2 meeting with the FDA regarding its once-weekly canvuparatide for chronic hypoparathyroidism. The company is set to initiate a Phase 3 trial in Q3 2026, focusing on a well-defined trial design that includes approximately 160 patients. Canvuparatide is positioned as a potential new standard of care in treating hypoparathyroidism, having received orphan drug designation from regulatory agencies in both the U.S. and Europe.
Read more →MBX▲ +5.6%on this news
MBX Biosciences to Participate in Upcoming March Investor Conferences
MBX Biosciences will participate in several investor conferences in March 2026, including the Citizens Life Sciences Conference and the UBS Biotech Summit. Key executives, including the CEO and CMO, will engage in discussions and meetings to present the company's advancements in precision peptide therapies. The events will take place in Miami, FL, highlighting MBX's commitment to investor relations.
Read more →MBX▼ -7.1%on this news
MBX Biosciences to Participate in Upcoming Investor Conferences
MBX Biosciences, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. CEO Kent Hawryluk and CMO Sam Azoulay will present at the Oppenheimer Annual Healthcare Life Sciences Conference and the TD Cowen Annual Health Care Conference. The company focuses on developing precision peptide therapies for endocrine and metabolic disorders.
Read more →MBX▼ -10.7%on this news
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
MBX Biosciences has appointed Laurie Stelzer as an independent director and chair of the audit committee. Stelzer brings extensive experience in financial leadership and corporate governance. The company anticipates a productive year ahead, including data from its clinical programs and the initiation of a Phase 3 trial for hypoparathyroidism. Stelzer's expertise is expected to complement the board's capabilities.
Read more →MBX▲ +15.2%on this news· ran to +29% by day 3
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
Read more →MBXand Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences' intellectual property protections; risks related to the competitive landscape for MBX
MBX Biosciences announced it will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company anticipates pivotal data including one-year follow-up results from its Phase 2 trial of canvuparatide for hypoparathyroidism and plans to initiate Phase 3 trials in Q3 2026. Additionally, MBX aims to expand its obesity pipeline with new candidates expected in 2026. As of December 31, 2025, MBX has a strong cash position projected to fund operations through 2029.
Read more →MBXMBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
MBX Biosciences, a clinical-stage biopharmaceutical company, announced that its CEO, Kent Hawryluk, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026. The conference will feature a company presentation and one-on-one meetings. MBX is focused on developing precision peptide therapies for endocrine and metabolic disorders.
Read more →MBXMBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
Read more →MBX▲ +9.7%on this news
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
MBX Biosciences announced positive topline results from its Phase 2 Avail™ trial of canvuparatide for hypoparathyroidism. The company raised $200 million in a public offering, providing a cash runway into 2029. Upcoming milestones include a Phase 3 trial initiation and clinical data for three Precision Endocrine Peptide™ programs in 2026.
Read more →MBX▲ +7.6%on this news· ran to +22% by day 3
MBX Biosciences to Participate in November Investor Conferences
MBX Biosciences will participate in several investor conferences in November 2025, including the Guggenheim Healthcare Innovation Conference and the Stifel Healthcare Conference. Key executives will present and engage in discussions, highlighting the company's focus on developing precision peptide therapies for endocrine and metabolic disorders. The events will also be accessible via live webcasts.
Read more →MBXMBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
MBX Biosciences will participate in the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025. CEO Kent Hawryluk and CMO Sam Azoulay will engage in a fireside chat, discussing the company's focus on precision peptide therapies for endocrine and metabolic disorders. The event will be accessible via a live webcast.
Read more →MBX▼ -13.8%on this newsshared move
MBX Biosciences Announces Pricing of Upsized Public Offering
MBX Biosciences has announced the pricing of its upsized public offering, consisting of 11,108,055 shares priced at $18.00 each. The offering is expected to yield gross proceeds of $199.9 million, with a closing date set for September 26, 2025. Underwriters have the option to purchase additional shares, enhancing the offering's potential.
Read more →MBX▼ -5.2%on this newsshared move
MBX Biosciences Announces Proposed Public Offering
MBX Biosciences has filed a registration statement for a proposed public offering of 10 million shares of common stock, with an option for underwriters to purchase an additional 1.5 million shares. The offering is contingent on market conditions and has not yet been priced. J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities are managing the offering.
Read more →MBX▲ +100%on this newsshared move
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
MBX Biosciences announced that its once-weekly canvuparatide achieved the primary endpoint in the Phase 2 Avail trial, showing a 63% responder rate at 12 weeks and a 79% responder rate at 6 months in the open-label extension. The treatment was well tolerated, with no serious adverse events. The company is preparing to initiate a Phase 3 trial in 2026.
Read more →MBX▲ +100%on this newsshared move
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
MBX Biosciences will announce topline results from its Phase 2 trial of canvuparatide for hypoparathyroidism on September 22. The company aims to address chronic hypoparathyroidism with a potential once-weekly treatment. An investor webcast will accompany the announcement, providing insights into the trial outcomes.
Read more →MBX▼ -10.3%on this news· ran to -21% by day 3
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
MBX Biosciences has initiated a Phase 1 trial for MBX 4291, a novel treatment for obesity. The trial aims to evaluate the safety and efficacy of this GLP-1/GIP co-agonist prodrug. The company anticipates topline results by 2027, highlighting the potential for improved weight loss and gastrointestinal tolerability compared to existing therapies.
Read more →MBXMBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Topline results for the Phase 2 Avail trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416)
MBX Biosciences reported its second-quarter financial results for 2025, highlighting significant clinical development milestones. The company is set to announce topline results from the Phase 2 Avail trial of canvuparatide for hypoparathyroidism in Q3 2025. Additionally, it expects to initiate a Phase 2a trial for imapextide and a Phase 1 trial for MBX 4291, both focused on metabolic disorders. Despite a net loss of $19.4 million, MBX maintains a robust cash position to support ongoing operations.
Read more →MBXMBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
MBX Biosciences has appointed Dr. Andreas Moraitis as Senior Vice President of Clinical Development. Dr. Moraitis brings extensive experience in endocrinology and clinical development, particularly in rare endocrine diseases. His leadership is expected to advance the company's lead product candidate, canvuparatide, which targets chronic hypoparathyroidism.
Read more →MBXMBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly admi
MBX Biosciences has submitted an Investigational New Drug (IND) application to the FDA for MBX 4291, a novel long-acting GLP-1/GIP receptor co-agonist prodrug intended for obesity treatment. The drug is designed for once-monthly administration, aiming to enhance patient adherence and gastrointestinal tolerability. A Phase 1 trial is planned to commence in Q3 2025, promising potential competitive advantages over existing therapies. This submission marks a key milestone in MBX's efforts to expand its pipeline in obesity treatments based on its proprietary PEP platform.
Read more →MBXMBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions
MBX Biosciences, a clinical-stage biopharmaceutical company, announced its participation at the American Diabetes Association's 85th Scientific Sessions scheduled for June 20-23, 2025, in Chicago. The company will present findings on MBX 1416, a glucagon-like peptide-1 receptor antagonist developed to treat post-bariatric hypoglycemia (PBH). Notably, MBX 1416 has demonstrated positive results in a Phase 1 trial, and a Phase 2 trial is anticipated to start in the latter half of 2025. These presentations will further elucidate the mechanism of action and potential benefits of MBX 1416.
Read more →MBXDisclaimer This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our product candidates, preclinica
MBX has presented an overview of its pipeline focused on precision endocrine peptides for managing endocrine and metabolic diseases. The company is advancing several drug candidates, including Canvuparatide for hypoparathyroidism and MBX 1416 for post-bariatric hypoglycemia, both of which target improving clinical outcomes and patient quality of life. MBX maintains a robust financial standing with significant funds raised and ongoing promising developments in its clinical pipeline. However, the success of these initiatives is contingent upon navigating regulatory challenges and a competitive marketplace.
Read more →MBXMBX Biosciences to Participate in June Investor Conferences
MBX Biosciences to Participate in June Investor Conferences
Read more →MBXMBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Topline results for the Phase 2 Avail evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investig
MBX Biosciences reported its first quarter financial results for 2025 alongside key corporate developments. The company announced that topline results for the Phase 2 Avail trial of canvuparatide in hypoparathyroidism patients are anticipated in the third quarter of 2025. Additionally, MBX 4291's IND application is on track for submission in Q2 2025, while a Phase 2 trial for MBX 1416 is expected to start in the latter part of the year. The company currently holds $240.8 million in cash, projected to fund operations through mid-2027.
Read more →MBX▲ +13.1%on this news
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
Read more →MBXMBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors Hoerter brings decades of pharmaceutical commercialization, leadership, and board experience to help guide MBX's next phase of
MBX Biosciences has appointed Steve Hoerter as an independent director to its Board of Directors. With over three decades in the pharmaceutical industry, Hoerter's experience includes leadership roles in successful biotech firms. The appointment is expected to strengthen MBX's strategic direction, particularly in the development of precision peptide therapies for endocrine and metabolic disorders. CEO Kent Hawryluk expressed confidence in Hoerter's ability to advance the company's growing pipeline.
Read more →MBXMBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Read more →MBXMBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights Enrollment complete in Phase 2 Avail trial of canvuparatide in hypoparathyroidism; topline results on track for
MBX Biosciences has reported its financial results for Q4 and the full year 2024, highlighting substantial progress across its clinical pipeline. The company completed patient enrollment for the Phase 2 Avail trial of its lead candidate, canvuparatide, with topline results expected in Q3 2025. Additionally, positive Phase 1 trial results for MBX 1416 support its upcoming Phase 2 study in post-bariatric hypoglycemia patients. The firm also plans to file an IND for MBX 4291 in obesity by Q2 2025, while maintaining a robust financial outlook with $262.1 million in cash resources.
Read more →MBXMBX Biosciences Announces Additions to Leadership Team
MBX Biosciences has appointed Chatan Charan, Ph.D., as Senior Vice President of Pharmaceutical Development and CMC, and Mark Hope as Senior Vice President of Regulatory and Quality. Both leaders bring extensive experience in drug development and regulatory affairs, which MBX expects will significantly contribute to advancing their pipeline of precision peptide therapeutics. The company is focused on developing new treatments for endocrine and metabolic disorders and has already initiated several clinical programs. These strategic appointments underscore MBX's commitment to growth and innovation in biotechnology.
Read more →MBX▲ +5.6%on this newsshared move
MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
Read more →MBXMBX Biosciences to Participate in March Investor Conferences
MBX Biosciences to Participate in March Investor Conferences
Read more →MBX▲ +8.1%on this news
MBX Biosciences to Participate in Upcoming February Investor Conferences
MBX Biosciences to Participate in Upcoming February Investor Conferences
Read more →MBX▼ -10.3%on this news· ran to -23% by day 3
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), w
MBX Biosciences announced positive topline results from the Phase 1 trial of its investigational drug MBX 1416, intended for the treatment of post-bariatric hypoglycemia (PBH). The trial indicated that MBX 1416 was well-tolerated among healthy volunteers, showcasing a favorable safety profile and pharmacokinetic results that support its potential for once-weekly dosing. Following these promising results, MBX plans to initiate a Phase 2 study in PBH patients in the second half of 2025, pending discussions with the FDA on their proposed study design.
Read more →MBX▼ -10.3%on this news· ran to -23% by day 3
MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Read more →MBXMBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Read more →MBX▼ -6.6%on this news
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism
Read more →MBX▼ -6.8%on this news
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Read more →MBXMBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject la
MBX Biosciences reported third quarter 2024 financial results, highlighting a total of $251.2 million raised from its upsized IPO and Series C financing. The company is on track with its clinical trials, expecting to complete enrollment for MBX 2109 in hypoparathyroidism by Q1 2025, with topline results anticipated in Q3 2025. Additionally, MBX 1416’s last subject visit is expected by late November, with results due in early January 2025. The firm maintains a strong cash position of $277.1 million, which supports operational sustainability into mid-2027.
Read more →MBX▼ -6.5%on this news
MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Biosciences to Participate in Upcoming November Investor Conferences
Read more →MBX▲ +8.5%on this news
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
MBX Biosciences has presented the rationale and design of its Phase 2 Avail™ trial for MBX 2109 at the ASBMR 2024 Annual Meeting. This trial, aimed at adults with hypoparathyroidism (HP), evaluates the safety, efficacy, and pharmacokinetics of MBX 2109, a potential long-acting replacement therapy. Dosing for the trial started in August 2024, with topline results expected in Q3 2025. The study's primary endpoint focuses on the discontinuation of active vitamin D and a reduction in calcium supplements while maintaining normal serum calcium levels.
Read more →MBX▼ -8.5%on this news
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Read more →MBXMBX Biosciences Announces Pricing of Initial Public Offering
MBX Biosciences Announces Pricing of Initial Public Offering
Read more →MBXMBX Biosciences Announces Launch of Initial Public Offering
MBX Biosciences Announces Launch of Initial Public Offering
Read more →MBXMBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism
MBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism
Read more →MBXMBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide (PEP) Platform
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide (PEP) Platform
Read more →MBXMBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
Read more →MBXMBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
Read more →MBXMBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Read more →MBXMBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
MBX Biosciences to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Read more →MBXMBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference
MBX Biosciences, a clinical stage biopharmaceutical company, announced its participation in the Piper Sandler 35th Annual Healthcare Conference. Kent Hawryluk, the company's CEO, will present at the event on November 29th, 2023, at 9:10 a.m. ET and will also host one-on-one investor meetings. This participation aims to enhance investor interest and showcase their Precision Endocrine Peptide therapeutics.
Read more →MBXMBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
Read more →MBXMBX Biosciences to Participate in Stifel 2023 Healthcare Conference
MBX Biosciences to Participate in Stifel 2023 Healthcare Conference
Read more →MBXMBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
Read more →MBXMBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Read more →MBXMBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting
Read more →MBXMBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
Read more →MBXMBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference
Read more →MBXMBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Read more →MBXMBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
Read more →MBXMBX Biosciences to Participate in Jefferies Healthcare Conference
MBX Biosciences, a clinical stage biopharmaceutical company, has announced its participation in the upcoming Jefferies Healthcare Conference, scheduled for June 8, 2023. The company's President and CEO, Kent Hawryluk, will present and conduct one-on-one meetings with investors. This event emphasizes MBX's focus on developing Precision Endocrine Peptide therapeutics for treating endocrine disorders.
Read more →MBXMBX Biosciences to Participate in May Investor Conferences
MBX Biosciences to Participate in May Investor Conferences
Read more →MBXMBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
Read more →MBXMBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
MBX Biosciences, a clinical stage biopharmaceutical company, is set to present at the Oppenheimer 33rd Annual Healthcare Conference. The event will occur virtually on March 14, 2023, with CEO Kent Hawryluk leading the presentation. This participation signifies MBX's active engagement in the healthcare sector and offers an opportunity to showcase their Precision Endocrine Peptide™ therapeutics. Such events are crucial for networking and gaining investor interest in the company's endeavors.
Read more →MBXMBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
Read more →MBXMBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Read more →MBXMBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Read more →MBXMBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
Read more →MBXMBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism
Read more →MBXMBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
Read more →MBXMBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
Read more →MBXMBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer
MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer
Read more →MBXMBX Biosciences Appoints James Cornelius to its Board of Directors
MBX Biosciences Appoints James Cornelius to its Board of Directors
Read more →MBXMBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases
MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases
Read more →Competitive Position
How MBX ranks across every disease it competes inCompetitive Position is a premium feature
See how MBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial